Monitoring kidney transplant rejection using blood DNA analysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the use of donor-derived cell-free DNA (dd-cfDNA) as a non-invasive diagnostic tool to monitor kidney transplant rejection. Researchers aim to quantify epigenetic signatures in the blood of kidney transplant patients to predict and characterize graft dysfunction. By analyzing the evolution of renal-specific cell-free DNA before and after transplantation, the study seeks to improve upon traditional methods that rely on invasive biopsies and non-specific markers. The goal is to enhance the accuracy of graft monitoring and reduce the need for invasive procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years old
* With end-stage renal failure
* Summoned for a kidney transplant at Pitié Salpêtrière Hospital
* Having been informed of the study and not objecting to the study having given free and informed written consent for the genetic analysis
* Benefiting from a social security scheme (excluding AME)

Exclusion Criteria:

Under legal protective measures (curatorship or guardianship, under judicial safeguard).

Where it's running

• Pitié-Salpétriêre Hospital
  Paris, Île-de-France Region, France Recruiting

Study contacts

• Study coordinator: Sarah Dr DROUIN, MD-PhD
• Email: sarah.drouin@aphp.fr
• Phone: +33 1 42 17 71 73

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Remote Ischemic Preconditioning at Different Times After Heart Valve Surgery

  This study tests whether applying brief, controlled blood-flow restrictions to a limb at different times after heart valve surgery can help protect organs and reduce complications like kidney injury.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07888634

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Biomarkers to predict CSA-AKI risk before heart surgery

  This study tests new biomarkers to see if they can predict CSA-AKI risk in adults undergoing cardiovascular surgery.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07811570

• Reducing Endotoxin Burden in Septic Shock Patients on CRRT with the oXiris Filter

  This trial tests whether using the oXiris hemofilter during continuous kidney replacement helps lower endotoxin levels in adults with septic shock who need CRRT.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07807410

• Perioperative GFR Monitoring to Predict CSA-AKI and CA-AKI

  This study tests whether perioperative transcutaneous fluorescence GFR measurements can predict CSA-AKI or CA-AKI in adults undergoing cardiovascular procedures or iodine contrast exposure.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07749417

• Restarting RAS inhibitors after AKI: a quick test in hospitalized adults

  This pilot study tests whether restarting renin-angiotensin system inhibitors early after acute kidney injury is feasible and safe in hospitalized adults already using these medicines.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT07734636

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.